Comparative Pharmacology
Head-to-head clinical analysis: BEOVU versus MVASI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BEOVU versus MVASI.
BEOVU vs MVASI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brolucizumab is a humanized monoclonal antibody Fab fragment that inhibits vascular endothelial growth factor (VEGF)-A, preventing its binding to VEGFR-1 and VEGFR-2 receptors, thereby reducing endothelial cell proliferation, neovascularization, and vascular permeability.
Monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), preventing binding to VEGFR-1 and VEGFR-2, thereby inhibiting angiogenesis and tumor growth.
0.5 mg (0.05 mL of 10 mg/mL solution) by intravitreal injection once every 4 weeks (monthly) for 12 months, then may be extended to once every 8 weeks (every 2 months) based on clinical response.
5 mg/kg intravenously every 2 weeks for metastatic colorectal cancer; 15 mg/kg intravenously every 3 weeks for non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer.
None Documented
None Documented
Terminal half-life approximately 26 days (range 23-31 days) in patients with neovascular age-related macular degeneration, supporting monthly intravitreal dosing.
Approximately 20 days (range 11–50 days); typical dosing interval every 2–3 weeks.
Primarily metabolic clearance; <1% excreted unchanged in urine. Biliary/fecal excretion not characterized for parent drug.
Primarily metabolized via reticuloendothelial system; no significant renal or biliary excretion of intact drug.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor